Retatrutide comparative results, long-acting TB medicine targets and climate-related health risks.
Metabolic research
Retatrutide improves glucose control and weight loss versus Ozempic in Phase III trial
Lilly reported that investigational retatrutide reduced HbA1c by 2.2 percentage points versus 1.8 with Ozempic at 80 weeks. Higher-dose retatrutide produced 20.9% weight loss versus 9.4%; detailed results are forthcoming, and the medicine remains unapproved.
Why it matters: Provides comparative evidence for diabetes treatment development, although complete safety data and regulatory assessment remain essential.
WHO sets development targets for long-acting injectable TB medicines
WHO published target profiles to guide injectable medicines for tuberculosis prevention and treatment. Goals include single-injection preventive treatment and disease treatment delivered through three or fewer dosing encounters over no more than four months; these are development targets, rather than approved regimens.
Why it matters: Gives developers and TB programmes shared benchmarks for efficacy, safety, affordability and simpler delivery, potentially reducing adherence barriers.
Lancet Countdown highlights accelerating climate-related health risks
The 2026 Lancet Countdown reports increasing health harms from heat, drought and other climate hazards. WHO’s account links heat to an estimated 710,000 deaths globally in 2023, while highlighting health benefits from cleaner energy and stronger early-warning systems.
Why it matters: Reinforces the need for climate-resilient healthcare facilities, heat preparedness and surveillance to protect vulnerable populations.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.